VOYAGE phase 3: Dupilumab significantly reduced asthma exace

VOYAGE phase 3: Dupilumab significantly reduced asthma exacerbations in children age 6-11


 E-Mail
ATS 2021, New York, NY - Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.
Dupilumab also rapidly improved lung function within two weeks, an improvement that was sustained for up to 52 weeks (the length of the trial), compared to placebo.
"We hope results from the VOYAGE trial will lay the groundwork for dupilumab as a potential new treatment option for patients aged 6 to 11 with moderate-to-severe asthma," said study author/investigator Leonard B. Bacharier, MD, professor of pediatrics, allergy/immunology/pulmonary medicine, Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center. "We also hope this study will lead to better characterization and understanding of the role of type 2 inflammation in asthma in pediatric patients."

Related Keywords

New York , United States , Monroe Carell Jr , Leonardb Bacharier , Regeneron Pharmaceuticals Inc , International Conference , Children Hospital At Vanderbilt University Medical Center , Monroe Carell , Vanderbilt University Medical , Regeneron Pharmaceuticals , Medicine Health , Immunology Allergies Asthma , Pulmonary Respiratory Medicine , Ediatrics , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , மன்ரோ கவனிப்பு ஜூனியர் , சர்வதேச மாநாடு , குழந்தைகள் மருத்துவமனை இல் வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ மையம் , மன்ரோ கவனிப்பு , வாண்டர்பில்ட் பல்கலைக்கழகம் மருத்துவ , மருந்து ஆரோக்கியம் ,

© 2025 Vimarsana